EARLY STAGE BREAST CANCER

This study tests a drug called trastuzumab deruxtecan, which delivers chemotherapy directly to cancer cells with low levels of HER2, either alone or with anastrozole (a hormone blocker). The goal is to see if these treatments can eliminate all signs of cancer before surgery in pe…

This study tests a shorter, 5-day radiation treatment for women aged 50 and older with early-stage breast cancer or DCIS. The goal is to see if this ultra-fast approach is as safe and effective as longer courses, with fewer side effects and less disruption to daily life. About 90…

This study is for women with a certain type of breast cancer (HER2-positive, hormone receptor-positive) who still have small amounts of cancer after initial treatment. It compares two drug combinations to see which works better at preventing the cancer from coming back. About 300…

This study is for women with an early, hormone-sensitive type of breast cancer that has a higher chance of coming back. It tests whether a blood test (ctDNA) can identify who can safely skip chemotherapy and instead take a targeted pill (dalpiciclib) plus hormone therapy. About 3…

This study tests whether taking statins can prevent heart problems caused by HER2-targeted therapy in women with early-stage breast cancer. About 60 participants will receive statins alongside their cancer treatment to see if it reduces treatment delays or early stops due to hear…

This study tests whether a 24-week exercise program (aerobic and strength training, 3 times a week) can help prevent breast cancer from returning in people with early-stage breast cancer. About 2,156 participants who have completed surgery and any chemotherapy or radiation will t…

This study tests whether adding a probiotic supplement called Biolosion to standard chemotherapy before surgery can help more people with early-stage triple-negative breast cancer achieve a complete remission. About 192 women will be randomly assigned to receive either standard t…

This study tests whether a diagnostic test called HER2DX can help doctors choose the best treatment for people with early-stage HER2-positive breast cancer. About 304 participants will be split into two groups: one gets standard treatment without the test results, and the other g…

This study looks at how different amounts of aerobic exercise (like walking or cycling) affect heart and lung fitness in post-menopausal women who had early stage breast cancer. About 152 women will take part. The goal is to find the best exercise plan to improve how well the bod…

This study looks at whether women with early-stage breast cancer can safely skip a drug called G-CSF during one part of their chemotherapy to reduce bone pain. About 242 participants will be randomly assigned to either take or skip the drug while on paclitaxel. The main goal is t…

This study tests a very short course of whole breast radiation given over just 5 days for women with early-stage breast cancer. Researchers want to see how the treatment affects the breast's appearance and how patients feel about their recovery and quality of life. 50 women who h…

This study looks at two ways to manage side effects from aromatase inhibitors, a hormone therapy for early-stage breast cancer. About half of women stop taking these drugs early due to side effects, raising the risk of cancer returning. The study will compare switching to a diffe…

This study looks at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. Finding this DNA, called minimal residual disease, may help predict if the cancer will come back. The study will follow 900 people with different types…

This study is for people with high-risk early-stage breast cancer. It tests whether taking a low dose of the drug azacitidine before surgery can increase immune cells (called TILs) inside the tumor. The goal is to see if the drug can make the immune system more active against the…

This study aims to match breast cancer patients with the most effective experimental drugs based on their tumor's unique features. Up to 5,000 participants will receive standard chemotherapy plus an experimental agent before surgery. Researchers will use MRI scans, tissue, and bl…